Hello User
Sign in
Hello
Sign Out
Subscribe
Next Story
Business News/ Markets / Stock Markets/  Lupin share price gains 92% in last one year to scale 52-week highs. Should you Buy, Sell or Hold the stock?

Lupin share price gains 92% in last one year to scale 52-week highs. Should you Buy, Sell or Hold the stock?

Stock market today-Lupin share price scaled 52 week highs having gained more than 90% in last one year on improved US sales outlook led by strong product range, new launches and lower competition.

Lupin share price scales 52 week highs on improved US sales outlook le by good product range, new launches and lower competition

Lupin share price with gains of more than 1% in morning trades scaled 52-week highs on Thursday. The stock has gained more than 90% in the last year helped by improved earnings outlook being driven by new launches and a strong pipeline of products for the US markets.

The US performance of Lupin has regularly seen an uptick led by lower competitive intensity being faced by its base business and strong performance by new launches.

Lupin during first half saw its revenue grow 25%. Nevertheless, net profits had grown multi folds to 942 Crore in H1FY24 from 40.7 Crore in H1FY23.

Also Read- Adani Ports share price gains over 2% as HSBC raises target after SC verdict on Hindenburg case

The company’s US portfolio is driving growth led by respiratory products and analysts see more gains. Lupin has been focusing on complex products to beat competitive intensity and drive growth. Its has also been growing its portfolio for developed markets through inorganic route too. Lupin had recently acquired brands like AARANE in Germany and NALCROM in Canada after having acquired respiratory assets as Xopenex and Brovana in the US market.

Lupin’s existing respiratory portfolio is gaining traction, where Albuterol is gaining market share in the generics segment at 22.9% and Arfomoterol market share stands at 32.8% in the branded generics portfolio as per analysts at Sharekhan . Lupin’s recent launches in the reparatory segment as generics of inhaler Spiriva in the US market, are also shaping well. The product does not face any significant competition.

Also Read- Coal India, ONGC, Oil India amongst top 10 PSU dividend yield stocks by Religare

USFDA has not granted exclusivity approval, but we do not foresee competitors until FY2026, said analysts at Sharekhan With assumption that generic Spiriva will not face price erosion pressure until FY2026 they build in $95 million and $100 miliion sales from Spiriva in FY2025 and FY2026, respectively. This will increase overall US sales to $835 mn and $1,000 mn sales, respectively said analysts at Sharekhan

Lupin's strong presence in domestic markets where it is growing well also cushions its outlook. Overall good US sales traction,

Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before taking any investment decisions

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed - it's all here, just a click away! Login Now!

ABOUT THE AUTHOR

Ujjval Jauhari

Ujjval Jauhari is a deputy editor at Mint, with over a decade of experience in newspapers and digital news platforms. He is skilled in storytelling, reporting, analysing and writing about stocks, investment ideas, markets, corporates and more. He is based in New Delhi.
Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
Get the latest financial, economic and market news, instantly.